Dr. Axel Merseburger presented “Predicting Survival of Men with Prostate Cancer after RP” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: prostate cancer, radical prostatectomy, survival
How to cite: Merseburger, Axel S. “Predicting Survival of Men with Prostate Cancer after RP” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://dev.grandroundsinurology.com/predicting-survival-men-prostate-cancer-rp.
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Dr. Merseburger is Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany. He previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School in Hanover, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002, following a 1-year academic research program in Washington, DC, where he finished his MD thesis. He completed a residency in surgery and urology at the Eberhard Karls University in Tübingen, Germany, and was a Research Fellow at the Miller School of Medicine in Miami, Florida, in 2006. Professor Merseburger accepted a position as a staff member in Hannover in 2008 and was promoted to Associate Professor in 2009 and full Professor in 2012. Professor Merseburger is board-certified in urology and is a member of numerous national and international urological and oncological associations. He also serves as a reviewer and member of the editorial board for many journals, and is Associate Editor of the World Journal of Urology. Furthermore, he is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer and has served as Chairman of the EAU Guideline Group for Lasers and Technologies. Professor Merseburger has won multiple awards, stipends, and prizes for his molecular and clinical research and has published more than 200 papers in peer-reviewed journals. His main area of interest is urologic oncology. Professor Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer, and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German phase II and III trials.
